Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oskooilar, Nader
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
Tong, My-Linh
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
Tong, My-Lin
No trials found